Jonathan brings deep expertise in biopharma consulting, scientific strategy, and global drug development to his role as Managing Partner and co-founder of Scitaris. He has innovated a variety of structured processes across indication and target strategy that have helped biotech and pharma clients deliver impactful solutions at the root, enabling teams to advance therapies that improve patient outcomes.

He earned his M.Sc. and Ph.D. summa cum laude through a joint program spanning five universities, including Cambridge UK, where he focused on complex biological interactions. His research contributions include being the first to extend the Cheng-Prusoff equation — used globally to determine IC50 values — to multivalent interactions between biological surfaces such as viruses and cells.